Modern approaches to the use of mesenchymal stem cells in oncohematology

Authors

  • Evgeniya A. Prymakova Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Svetlana I. Krivenko Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Viktorya V. Smolnikova Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Ekaterina A. Nazarova Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Alla A. Symanovich Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Ekaterina G. Yurkina Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Nataliya I. Dedyulya Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Iryna A. Romanova Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
  • Natalya F. Milanovich Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

Keywords:

graft-versus-host disease, mesenchymal stem cells, biomedical cell product, subpopulation composition of lymphocytes

Abstract

In recent decades, views on etiology and pathogenesis of hemoblastosis have changed significantly. Unfavorable environmental factors (both physical and chemical) are becoming increasingly important etiologically. The strategy and tactics of treatment of oncohematological diseases are constantly being improved, and hematopoietic stem cell transplantation remains the «gold standard» in the treatment of this pathology. The main limitation of hematopoietic stem cell transplantation is the development of one of the most severe complications, the graft-versus-host disease. Cell therapy, in which mesenchymal stem cells play a leading role, is currently the second line of therapy for this condition after corticosteroids. It is necessary to optimize the approach to choosing a biomedical cell product based on mesenchymal stem cells in order to increase the effectiveness of cell therapy. The present study analyzes changes in the subpopulation composition of lymphocytes from recipients of allogeneic hematopoietic stem cells with signs of a graft-versus-host disease when they are co-cultured with mesenchymal stem cells obtained from different donors. It has been shown that cultures of mesenchymal stem cells obtained from different donors have different immunoregulatory potential. A method is proposed that makes it possible to select the most suitable biomedical cell product based on mesenchymal stem cells in terms of immunological characteristics for the clinical application of the graft-versus-host reaction. The analysis of the effectiveness of the proposed method was carried out using the results of immunophenotyping of lymphocytes from 12 recipients of allogeneic hematopoietic stem cells with clinical manifestations of GVHD treated at the State Institution «MSPC ST and H».

Author Biographies

  • Evgeniya A. Prymakova, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

    clinical laboratory diagnostics doctor of the cell biotechnology laboratory.

  • Svetlana I. Krivenko, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

    doctor of science (medicine), professor; deputy director for research.

  • Viktorya V. Smolnikova, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

    PhD (biology), docent; leading researcher of science department.

  • Ekaterina A. Nazarova, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

    PhD (biology), clinical laboratory diagnostics doctor of the cell biotechnology laboratory.

  • Alla A. Symanovich, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

    PhD (biology), docent; clinical laboratory diagnostics doctor of the cell biotechnology laboratory.

  • Ekaterina G. Yurkina, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

    senior researcher of science department.

  • Nataliya I. Dedyulya, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

    PhD (biology), docent; head of the cell biotechnology laboratory.

  • Iryna A. Romanova, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

    researcher of science department.

  • Natalya F. Milanovich, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

    PhD (medicine), docent; head of the hematology department of bone marrow transplantation No. 3.

References

  1. Arai S, Margolis J, Zahurak M. Poor outcome in steroid-refractory graftversus-host disease with antithymocyte globulin treatment. Biology and Blood Marrow Transplantation. 2002;8:155–160.
  2. Levine JE, Logan B, Wu J. Graft-versus-host disease treatment: predictors of survival. Biology and Blood Marrow Transplantation. 2010;16:1693–1699.
  3. Westin JR, Saliba RM, De Lima M. Steroid-refractory acute GVHD: Predictors and outcomes. Advances in Hematology. 2011;2011:8.
  4. Dotoli GM, De Santis GC, Orellana MD. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2017;52(6):859–862.
  5. Ball LM, Bernardo ME, Roelofs H. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. British Journal of Haematology. 2013;163:501–509.
  6. Le Blanc K, Rasmusson I, Sundberg B. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363(2004):1439–1441.
  7. Le Blanc K, Frassoni F, Ball L. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579–1586.
  8. Yanez R, Lamana ML, Garcia-Castro J. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006;24:2582–2591.
  9. DelaRosa O, Sa´nchez-Correa B, Morgado S. Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells and Development. 2012;21(8):1333–1343.
  10. Glennie S, Soeiro I, Dyson PJ. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2005;105:2821–2827.
  11. Nauta AJ, Kruisselbrink AB, Lurvink E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. The Journal of Immunology. 2006;177:2080–2087.
  12. Corcione A, Benvenuto F, Ferretti E. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367–372.
  13. Salem HK, Thiemermann C. Mesenchymal stromal cells: Current understanding and clinical status. Stem Cells. 2010;28:585–596.
  14. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499-3506.
  15. Munneke JM, Spruit MJA, Cornelissen AS. The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid- Refractory Acute Graft-Versus-Host Disease. Transplantation. 2016;100(11):2309–2314.
  16. Galipeau J, Sense´be´ L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018;22(6):824–833.
  17. Maged G, Abdelsamed MA, Wang H. The potency of mesenchymal stem/stromal cells: does donor sex matter? Stem Cell Research & Therapy. 2024;15(1):112.
  18. Carvalho AÉS, Sousa MRR, Alencar-Silva T. Mesenchymal stem cells immunomodulation: The road to IFN-γ licensing and the path ahead. Cytokine & Growth Factor Reviews. 201;47:32–42.
  19. Primakova EA, Krivenko SI, Symanovich AA. Citokiny plazmy krovi kak potencial’nye biomarkery reakcii «transplantat protiv hozjaina» v rannem posttransplantacionnom periode [Plasma Cytokines as Potential Biomarkers of Graft-Versus-Host Disease in the Early Posttransplant Period]. Novosti mediko-biologicheskih nauk. 2023;2:55–61. Russian.

Downloads

Published

2025-07-15

Issue

No. 2 (2025): Journal of the Belarusian State University. Ecology

Section

Medical Ecology

How to Cite

[1]
Prymakova, E. et al. 2025. Modern approaches to the use of mesenchymal stem cells in oncohematology. Journal of the Belarusian State University. Ecology. 2 (Jul. 2025), 68–77.